← Back to Search

LymphaTech Scanner for Breast Cancer-Related Lymphedema

N/A
Recruiting
Led By Alphonse G. Taghian, MD
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participants must have histologically or cytologically confirmed invasive or in-situ carcinoma of the breast and will undergo unilateral breast cancer surgery
Age >18 years.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 years
Awards & highlights

Study Summary

This trial will compare how much extra lymph fluid is in the arms of people who have had breast cancer surgery, using two different machines.

Who is the study for?
This trial is for adults over 18 with invasive or in-situ breast cancer who are scheduled for unilateral breast surgery. They must be able to stand unaided and move their arm sideways, understand the study, and verbally agree to participate. Excluded are those with primary lymphedema, current cellulitis, severe illnesses like heart failure or unstable angina, psychiatric issues affecting compliance, or brain metastases.Check my eligibility
What is being tested?
The study is testing the effectiveness of the LymphaTech Scanner compared to the Perometer for measuring upper extremity volume in patients who have had breast cancer. It aims to determine if LymphaTech can accurately screen for lymphedema after breast surgery.See study design
What are the potential side effects?
Since this trial involves non-invasive measurements rather than drug treatments, there are no direct side effects from interventions like medications. However, discomfort during measurement due to arm movement may occur.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have breast cancer confirmed by tests and will have surgery on one breast.
Select...
I am older than 18 years.
Select...
I am older than 18 years.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Precision and reliability
Secondary outcome measures
Measurement Time

Trial Design

1Treatment groups
Experimental Treatment
Group I: Breast Cancer-Related Lymphedema MeasurementsExperimental Treatment1 Intervention
Absolute volume of the upper extremities will be assessed using the LymphaTech Scanner and the Perometer.

Find a Location

Who is running the clinical trial?

Massachusetts General HospitalLead Sponsor
2,931 Previous Clinical Trials
13,198,345 Total Patients Enrolled
80 Trials studying Breast Cancer
132,812 Patients Enrolled for Breast Cancer
Heinz Family FoundationUNKNOWN
2 Previous Clinical Trials
182 Total Patients Enrolled
2 Trials studying Breast Cancer
182 Patients Enrolled for Breast Cancer
Alphonse G. Taghian, MDPrincipal InvestigatorDana-Farber Cancer Institute
1 Previous Clinical Trials
142 Total Patients Enrolled
1 Trials studying Breast Cancer
142 Patients Enrolled for Breast Cancer

Media Library

Breast Cancer-Related Lymphedema Measurements Clinical Trial Eligibility Overview. Trial Name: NCT03861975 — N/A
Breast Cancer Research Study Groups: Breast Cancer-Related Lymphedema Measurements
Breast Cancer Clinical Trial 2023: Breast Cancer-Related Lymphedema Measurements Highlights & Side Effects. Trial Name: NCT03861975 — N/A
Breast Cancer-Related Lymphedema Measurements 2023 Treatment Timeline for Medical Study. Trial Name: NCT03861975 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are participants still being recruited for this clinical investigation?

"Yes, according to clinicaltrials.gov this experiment is actively enrolling subjects. This trial was posted on the 30th of January 2019 and its last update occurred on May 2nd 2022."

Answered by AI

Are there any limitations on the number of participants in this investigation?

"Affirmative. Clinicaltrials.gov reveals that this clinical trial, which was first publicized on January 30th 2019, is actively recruiting participants. The study necessitates 100 patients from a single medical institution."

Answered by AI

Who else is applying?

What state do they live in?
Massachusetts
How old are they?
18 - 65
What site did they apply to?
Massachusetts General Hospital Cancer Center
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Exploring the Efficacy and Feasibility of the LymphaTech Scanner for Breast Cancer-Related Lymphedema Screening
Alphonse Taghian 2019. "Exploring the Efficacy and Feasibility of the LymphaTech Scanner for Breast Cancer-Related Lymphedema Screening". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03861975.
All > Breast Cancer Boston > Lymphedema
~2 spots leftby May 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top